Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco

Dooley, Kelly E.; Lahlou, Ouafae; Ghali, Iraqi; Knudsen, Janine; Elmessaoudi, My Driss; Cherkaoui, Imad; Aouad, Rajae El
January 2011
BMC Public Health;2011, Vol. 11 Issue 1, p140
Academic Journal
Background: Patients with tuberculosis require retreatment if they fail or default from initial treatment or if they relapse following initial treatment success. Outcomes among patients receiving a standard World Health Organization Category II retreatment regimen are suboptimal, resulting in increased risk of morbidity, drug resistance, and transmission. In this study, we evaluated the risk factors for initial treatment failure, default, or early relapse leading to the need for tuberculosis retreatment in Morocco. We also assessed retreatment outcomes and drug susceptibility testing use for retreatment patients in urban centers in Morocco, where tuberculosis incidence is stubbornly high. Methods: Patients with smear- or culture-positive pulmonary tuberculosis presenting for retreatment were identified using clinic registries in nine urban public clinics in Morocco. Demographic and outcomes data were collected from clinical charts and reference laboratories. To identify factors that had put these individuals at risk for failure, default, or early relapse in the first place, initial treatment records were also abstracted (if retreatment began within two years of initial treatment), and patient characteristics were compared with controls who successfully completed initial treatment without early relapse. Results: 291 patients presenting for retreatment were included; 93% received a standard Category II regimen. Retreatment was successful in 74% of relapse patients, 48% of failure patients, and 41% of default patients. 25% of retreatment patients defaulted, higher than previous estimates. Retreatment failure was most common among patients who had failed initial treatment (24%), and default from retreatment was most frequent among patients with initial treatment default (57%). Drug susceptibility testing was performed in only 10% of retreatment patients. Independent risk factors for failure, default, or early relapse after initial treatment included male gender (aOR = 2.29, 95% CI 1.10-4.77), positive sputum smear after 3 months of treatment (OR 7.14, 95% CI 4.04-13.2), and hospitalization (OR 2.09, 95% CI 1.01-4.34). Higher weight at treatment initiation was protective. Male sex, substance use, missed doses, and hospitalization appeared to be risk factors for default, but subgroup analyses were limited by small numbers. Conclusions: Outcomes of retreatment with a Category II regimen are suboptimal and vary by subgroup. Default among patients receiving tuberculosis retreatment is unacceptably high in urban areas in Morocco, and patients who fail initial tuberculosis treatment are at especially high risk of retreatment failure. Strategies to address risk factors for initial treatment default and to identify patients at risk for failure (including expanded use of drug susceptibility testing) are important given suboptimal retreatment outcomes in these groups.


Related Articles

  • Tuberculosis Recurrence and Mortality after Successful Treatment: Impact of Drug Resistance. Cox, Helen; Kebede, Yared; Allamuratova, Sholpan; Ismailov, Gabit; Davletmuratova, Zamira; Byrnes, Graham; Stone, Christine; Niemann, Stefan; Rüsch-Gerdes, Sabine; Blok, Lucie; Doshetov, Daribay // PLoS Medicine;Oct2006, Vol. 3 Issue 10, p1836 

    Background The DOTS (directly observed treatment short-course) strategy for tuberculosis (TB) control is recommended by the World Health Organization globally. However, there are few studies of long-term TB treatment outcomes from DOTS programs in high-burden settings and particularly settings...

  • Addressing the threat of tuberculosis caused by extensively drug-resistant Mycobacterium tuberculosis.  // Weekly Epidemiological Record;10/13/2006, Vol. 81 Issue 41, p386 

    The article discusses different health measures taken by the World Health Organization (WHO) to address the threat of tuberculosis caused by multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. In 2000, WHO and its partner agencies set up a committee that aimed to...

  • Global Surveillance for Antituberculosis-Drug Resistance, 1994—1997. Pablos-Méndez, Ariel; Raviglione, Mario C.; Laszlo, Adalbert; Binkin, Nancy; Rieder, Hans L.; Bustreo, Flavia; Cohn, David L.; Lambregts-van Weezenbeek, Catherina S.B.; Kim, Sang Jae; Chaulet, Pierre; Nunn, Paul // New England Journal of Medicine;06/04/98, Vol. 338 Issue 23, p1641 

    Background: Drug-resistant tuberculosis threatens efforts to control the disease. This report describes the prevalence of resistance to four first-line drugs in 35 countries participating in the World Health Organization–International Union against Tuberculosis and Lung Disease Global...

  • Mycobacterium tuberculosis... Can we beat it? Maitra, Arundhati; Bhakta, Sanjib // Virulence; 

    The article discusses the highlights of the conference titled Mycobacterium tuberculosis...can we beat it? which was organized by Euroscicon conference commemorating World TB Day which took place on March 21, 2013. A report on global tuberculosis released by the World Health Organization (WHO)...

  • Doctors argue over detention of patients with XDR-TB. Moszynski, Peter // BMJ: British Medical Journal (International Edition);2/3/2007, Vol. 334 Issue 7587, p228 

    The article reports that the World Health Organization has issued new guidance on the treatment of patients with extensively drug resistant tuberculosis (XDR-TB) after it was suggested that people may need to be involuntarily detained to prevent a virtually untreatable disease from emerging....

  • Apego al tratamiento y el desarrollo de fármacoresistencia. Limitaciones y necesidades para el desarrollo de estrategias para el control efectivo de la tuberculosis. García-García, Ma. de Lourdes // Salud Pública de México;mar/abr2007 suppleme, Vol. 49, pE127 

    Tuberculosis was identified as a global problem in 1993 and is the second cause of death produced by a single pathogen. The main obstacles to achieve an adequate control are poor performance of local programs, lack of treatment compliance, appearance of drug-resistant Mycobacterium tuberculosis...

  • New Tuberculosis Drugs in Development. Laughon, Barbara E. // Current Topics in Medicinal Chemistry;Mar2007, Vol. 7 Issue 5, p463 

    Over the past 50 years, no new drug classes have been introduced to treat tuberculosis. Tuberculosis (TB) kills nearly two million people a year mainly in the poorest communities in the developing world. It afflicts millions more. About one third of the world's population is silently infected...

  • WHO calls for countries to develop five year plans to tackle multidrug resistant tuberculosis. Perry, Jane // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;4/11/2009, Vol. 338 Issue 7699, p851 

    The article discusses a call to fight multidrug resistant tuberculosis (MDRTB) and extensively drug resistant tuberculosis (XDRTB) by health ministers and delegations from 30 countries who attended a meeting in Beijing, China. The meeting was organized by the World Health Organization (WHO), the...

  • Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa. Shah, Maunank; Chihota, Violet; Coetzee, Gerrit; Churchyard, Gavin; Dorman, Susan E. // BMC Infectious Diseases;2013, Vol. 13 Issue 1, p1 

    Background: The World Health Organization has endorsed the use of molecular methods for the detection of TB and drug-resistant TB as a rapid alternative to culture-based systems. In South Africa, the Xpert MTB/Rif assay and the GenoType MTBDRplus have been implemented into reference laboratories...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics